2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4284 Multicenter real-world data analysis of post-transplant treatment with asciminib in advanced stage Philadelphia-positive leukemia including advanced stage CML and Ph+ acute leukemia

Mohamed Isam Sharif, MD, Elza Lomaia, MD, PhD, DrSci2, Julia Vlasova3, Daniel Wolff, MD4, Kathrin Reuthner, MD5, Francesca Bonifazi6, Ahmet Emre Eskazan, MD7, Osman Sahin8, Mehmet Pepeler, MD9, Leylagül Kaynar, MD10, Ayman Saad, MD11, Sarah Altayyari, MD, MRCPI12, Mohsen Alzahrani Sr, MD13, Mohamed Abu Haleeqa, MD14, Guillermo Orti, MD15, Acy Quixada, MD16, Olga Kulemina, MD17, Ekaterina Ovsyannikova18, Ivan Moiseev, MD, PhD19, Elena Morozova20, Dennis Dong Hwan Kim, MD, PhD21
1 Division of Hematology, Department of Medicine, University of Toronto; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
2 Almazov National Medical Research Centre, Saint-Petersburg, Russian Federation
3 Raisa Gorbacheva Memorial Institute of Children’s Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation
4 Department of Internal Medicine III, University Hospital Regensburg, University of Regensburg, Regensburg, Germany
5 Department of Internal Medicine III, University Hospital Regensburg, University of Regensburg, Regensburg, Germany
6 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
7 Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
8 Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Adana Baskent University., Adana, Turkey
9 Department of Hematology, Ankara Bilkent City Hospital, Ankara, Turkey
10 Department of Hematology, Faculty of Medicine, Istanbul Medipol University., Istanbul, Turkey
11 King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia
12 King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia
13 Department of Oncology and Hematology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
14 Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab Emirates
15 Vall d´Hebron University Hospital, Barcelona, Spain
16 Hematology and Bone Marrow Transplant Service, Walter Cantidio University Hospital / Federal University of Ceara, Fortaleza, Brazil
17 Almazov National Medical Research Centre, Saint-Petersburg, Russian Federation
18 Almazov National Medical Research Centre, Saint-Petersburg, Russian Federation
19 Raisa Gorbacheva Memorial Institute of Children’s Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation
20 Raisa Gorbacheva Memorial Institute of Children’s Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation
21 Division of Hematology, Department of Medicine, University of Toronto; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Introduction: Post-transplant relapse is a primary cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) in Philadelphia chromosome-positive (Ph+) leukemias. While tyrosine kinase inhibitors (TKIs) are used for post-HCT maintenance or preemptive therapy, traditional ATP-site TKIs often cause myelosuppression, gastrointestinal, hepatic, or cutaneous toxicities that mimic or exacerbate graft-versus-host disease (GvHD).

Asciminib is a first-in-class myristoyl pocket inhibitor, with activity against multiple ATP-site resistant mutations. Owing to its excellent tolerability and lack of GI, hepatic, or cutaneous toxicities, Asciminib emerged as a particularly attractive therapeutic modality for post-transplant maintenance or preemptive purpose. However, its clinical data for therapeutic efficacy, toxicity and long-term outcomes as post-transplant regimen remains very limited, any prospective study is not planned.

Methods: We conducted a multicenter retrospective analysis evaluating the efficacy and safety of post-HCT asciminib. Patients with advanced-stage CML or Ph+ ALL/AML/MPAL were analyzed by therapeutic intent: maintenance (starting at BCR-ABL qPCR below MR4), preemptive (starting at MR2-3), or relapse therapy (rapidly rising molecular levels or above MR2). Outcomes included relapse-free survival (RFS), overall survival (OS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and toxicity-related modifications.

Results: Sixty-three patients across 9 countries were included (median age 39 years; 49% male). Diagnoses included CML (n=56; 10 accelerated, 8 blastic phase), Ph+ ALL (n=5), and AML (n=1). Prior to HCT, 22 patients (35%) harbored ABL1 mutations, predominantly T315I (n=16). Asciminib was initiated at a median of 170 days post-HCT for maintenance (n=34), preemptive (n=14), or relapse therapy (n=9), using standard (n=42; 20/40/80mg daily) or high dose (n=13; 160/200/400mg daily).

Treatment was well tolerated; only 5 patients required dose reductions, and 4 discontinued due to adverse events. Key toxicities included anemia (19%), neutropenia (11%), thrombocytopenia (25%), non-hematologic toxicities (21%), and GvHD flare-ups (5%).

At a median follow-up of 21 months, 20 relapse events (32%) occurred including resistance (n=6) and progression (n=14) including 3 cases of extramedullary relapse. At relapse, ABL1 KDM test demonstrated 7 patients carrying ABL1 KD mutations including 2 newly emerging mutant cases of E292V and E459K with persistent T315I or F317L. While 28 remained on asciminib (44%) at last follow-up, 28 discontinued it: 10 patients completed planned treatment (median 10 months duration), relapse/progression (n=10), sepsis (n=4), GvHD flare-up (n=2), pulmonary thromboembolism (n=1).

The 2-year RFS was 65.5%, significantly favoring maintenance (76%) over preemptive/relapse therapy (46%; p=0.065). The 2-year OS also favored maintenance (79% vs 61%; p=0.09). The 2-year CIR was 21.5%, showing a significant benefit from maintenance (6.6%) over preemptive (35.7%) and relapse cohorts (68.9%; p=0.0275).

Dose-response analysis showed that maintenance was highly effective regardless of dose, whereas preemptive therapy showed a trend toward superior RFS with high-dose asciminib (60% vs 44%). Relapse therapy yielded poor RFS across all doses.

Conclusion: 1) Post-HCT asciminib is feasible and well-tolerated with low toxicity-driven discontinuation rates. 2) Maintenance and preemptive strategies provide encouraging disease control. 3) Standard dosing seems sufficient for maintenance, while preemptive intervention may benefit from higher dose Asciminib. Relapse therapy yields poor outcomes with monotherapy, indicating a need for combination strategies.

Dennis Dong Hwan Kim, MD, PhD: Novartis - Research Funding; Enliven - Research Funding; Abbvie - Research Funding; Incyte - Research Funding; Sanofi - Research Funding; Ascentage - Research Funding; JAZZ - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); J&J - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony)